imipenem, anhydrous has been researched along with Acute Lung Injury in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, DG; Kong, DP; Su, L; Tu, Y; Wang, ZB; Zhang, CX; Zhang, WN; Zhuang, CL | 1 |
| Addison, MP; Choudhury, S; Darzi, SA; Dash, JR; Kandasamy, K; Kasa, JK; Maruti, BS; Mishra, SK; Parida, S; Singh, TU; Singh, V | 1 |
2 other study(ies) available for imipenem, anhydrous and Acute Lung Injury
| Article | Year |
|---|---|
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
Topics: Acute Lung Injury; Animals; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Repositioning; Guanine; Humans; Imipenem; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Pandemics; Pneumonia, Viral; Tumor Necrosis Factor-alpha | 2020 |
Atorvastatin along with imipenem attenuates acute lung injury in sepsis through decrease in inflammatory mediators and bacterial load.
Topics: Acute Lung Injury; Animals; Atorvastatin; Bacterial Load; Drug Therapy, Combination; Imipenem; Inflammation Mediators; Male; Mice; Sepsis | 2015 |